Chih-Ming Liao Chienjin Huang James R. Winton Zeng-Weng Chen Wei-Cheng Lee Jiunn-Wang Liao Ter-Hsin Chen Chwei-Jang Chiou Kuang-Sheng Yeh Maw-Sheng Chien Shih-Ling Hsuan 2009 <p><span>The efficacy of a novel vaccine composed of three short recombinant subunit </span><i>Pasteurella multocida</i><span> toxin (PMT) proteins in combination with a bi-valent </span><i>P. multocida</i><span> whole-cell bacterin (rsPMT–PM) was evaluated in field studies for prevention and control of progressive atrophic rhinitis (PAR) of swine at 15 conventional farrow-to-finish farms. Experimental piglets that were immunized twice with the rsPMT–PM vaccine developed detectable titers of neutralizing antibodies (greater than 1:8) that prevented the growth retardation and pathological lesions typically observed following challenge with authentic PMT. A total of 542 sows were vaccinated once or twice prior to parturition and serum neutralizing antibody titers were evaluated. Both single and double vaccination protocols induced neutralizing antibody titers of 1:16 or higher in 62% and 74% of sows, respectively. Notably, neither sows nor piglets at a farm experiencing a severe outbreak of PAR at the time of the vaccination trial had detectable antibody titers, but antibody titers increased significantly to 1:16 or higher in 40% of sows following double vaccination. During the year after vaccination, clinical signs of PAR decreased in fattening pigs and growth performance improved sufficiently to reduce the rearing period until marketing by 2 weeks. Collectively, these results indicate that the rsPMT–PM vaccine could be used to provide protective immunity for controlling the prevalence and severity of PAR among farm-raised swine.</span></p> application/pdf 10.1016/j.vaccine.2009.03.005 en Elsevier Efficacy of a novel Pasteurella multocida vaccine against progressive atrophic rhinitis of swine article